Ovid Therapeutics (OVID) Operating Margin (2020 - 2025)
Historic Operating Margin for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to 9487.12%.
- Ovid Therapeutics' Operating Margin fell 18420300.0% to 9487.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 625.47%, marking a year-over-year decrease of 5944100.0%. This contributed to the annual value of 10933.75% for FY2024, which is 41889600.0% up from last year.
- Per Ovid Therapeutics' latest filing, its Operating Margin stood at 9487.12% for Q3 2025, which was down 18420300.0% from 80.88% recorded in Q2 2025.
- Ovid Therapeutics' 5-year Operating Margin high stood at 84.73% for Q1 2021, and its period low was 115329.27% during Q3 2022.
- Its 5-year average for Operating Margin is 14689.89%, with a median of 9487.12% in 2025.
- The largest annual percentage gain for Ovid Therapeutics' Operating Margin in the last 5 years was 1042934900bps (2023), contrasted with its biggest fall of -207561800bps (2023).
- Ovid Therapeutics' Operating Margin (Quarter) stood at 11.92% in 2021, then soared by 54bps to 5.47% in 2022, then crashed by -49bps to 8.16% in 2023, then plummeted by -93551bps to 7645.09% in 2024, then dropped by -24bps to 9487.12% in 2025.
- Its last three reported values are 9487.12% in Q3 2025, 80.88% for Q2 2025, and 9653.85% during Q1 2025.